Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000171.xml
Dtsch Med Wochenschr 2016; 141(11): 768-771
DOI: 10.1055/s-0042-107202
DOI: 10.1055/s-0042-107202
Klinischer Fortschritt
Hämatologie und Onkologie
Therapie des metastasierten malignen Melanoms
Treatment of metastatic malignant melanomaAuthors
Further Information
Publication History
Publication Date:
02 June 2016 (online)
-
Literatur
- 1 Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: II Sun exposure. Eur J Cancer 2005; 41: 45-60
- 2 Balch CM, Gerschenwald JE, Soong SJ et al. Final Version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 2009; 27: 6199-6206
- 3 Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516
- 4 Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365
- 5 Chapman PB, Hauschild A, Robert C et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival – results of the BRIM-3 study. Pigment Cell Melanoma Res 2015; 28: 753-826
- 6 Larkin J, Ascierto PA, Dréno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Eng J Med 2014; 371: 1867-1876
- 7 Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-1888
- 8 Hodi JS, O’Day SJ, McDermott DR et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-712
- 9 Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330
- 10 Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532
- 11 Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-2017
- 12 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34